Personalized Therapy

Make a calculated first move.

Interventional Oncology / Cancer Therapies & Ablation / TheraSphere / Personalized Therapy

Personalized Dosing is Linked to Optimized Results

When you can calculate each dose specifically to the needs of each patient, you’re better able to improve tumor* response and optimize outcomes. TheraSphere equips you with a dialed-in individualized dose that’s ready to use and easy to administer.

Personalized Dosimetric Approach Improves Overall Survival

Dr Salem-Impact of DOSISPHERE-01 Trial.
Riad Salem, MD, Chief of Vascular Interventional Radiology at Northwestern Medicine discusses the DOSISPHERE-01 trial.
Professor Garin-DOSISPHERE-01: An Innovative Trial Design.
Professor Etienne Garin, Principal Investigator of the DOSISPHERE-01 trial, discusses the innovative design of the trial and what makes it unique. 
Watch the DOSISPHERE-01 Trial Data.












DOSISPHERE-01 Trial Summary

Administration of a personalized, multicompartment TheraSphere dose in the Level I prospective, randomized study, DOSISPHERE-01, showed a 26.6 month overall survival for large HCC tumor* patients.1

Simplicit90Y™ Personalized Dosimetry Software

Simplicit90Y is the only Y-90 personalized dosimetry software with FDA 510K  clearance, designed specifically for TheraSphere™ Y-90 Glass Microspheres. Simplicit90Y was developed to accelerate dosimetry planning and improve your Y-90 Selective Internal Radiation Therapy (SIRT) workflow.

Simplicit90Y™ Personalized Dosimetry Software image.


Hear From Y-90 Leaders

Dr Salem-A Unique Infusion of Microspheres for Unique Tumors.
Riad Salem, MD an Interventional Radiologist at Northwestern Memorial Hospital talks about using TheraSphere to personalize treatment and optimize dosimetry.
Dr Tablri-Transforming the Odds for a Transplant Patient.
Nora Tabori, MD shares her experience helping a young transplant patient. “I’ve bridged several patients to transplant at this point that were not previously considered transplant patients.” Dr. Tabori shares the story of a young woman who wasn’t a great surgical candidate. Two years after treating her with TheraSphere she’s still doing well.
  1. Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29 

    *Refers to HCC or associated tumors